Socioeconomic, Clinical, and Molecular Features of Breast Cancer Influence Overall Survival of Latin American Women

• Autores: de Almeida, Liz María; Cortés, Sandra; Vilensky, Marta; Valenzuela, Olivia; Cortes Sanabria, Laura; de Souza, Mirian; Barbeito, Rafael Alonso; Abdelhay, Eliana; Artagaveytia, Nora; Daneri Navarro, Adrian; Llera, Andrea Sabina; Müller, Bettina; Podhajcer, Osvaldo Luis; Velazquez, Carlos; Alcoba, Elsa; Alonso, Isabel; Bravo, Alicia I.; Camejo, Natalia; Carraro, Dirce Maria; Castro, Mónica; Cataldi, Sandra; Cayota, Alfonso; Cerda, Mauricio; Colombo, Alicia; Crocamo, Susanne; Silva-Garcia, Aida A.; Viña, Stella; Zagame, Livia; Jones, Beth; Szklo, Moysés
• Año de publicación: 2022
• Idioma: inglés
• Tipo de recurso: artículo
• Materia: BREAST CANCER; GLOBAL EXCELLENCE; LATIN AMERICA; MOLECULAR SUBTYPES; ONCOLOGY; PROGNOSIS; RISK FACTORS
• Institución: Consejo Nacional de Investigaciones Científicas y Técnicas

Molecular profile of breast cancer in Latin-American women was studied in five countries: Argentina, Brazil, Chile, Mexico, and Uruguay. Data about socioeconomic characteristics, risk factors, prognostic factors, and molecular subtypes were described, and the 60- month overall cumulative survival probabilities (OS) were estimated. From 2011 to 2013, 1,300 eligible Latin-American women 18 years or older, with a diagnosis of breast cancer in clinical stage II or III, and performance status ≦̸ 1 were invited to participate in a prospective cohort study. Face-to-face interviews were conducted, and clinical and outcome data, including death, were extracted from medical records. Unadjusted associations were evaluated by Chi-squared and Fisher’s exact tests and the OS by Kaplan–Meier method. Log-rank test was used to determine differences between cumulative probability curves. Multivariable adjustment was carried out by entering potential confounders in the Cox regression model. The OS at 60 months was 83.9%. Multivariable-adjusted death hazard differences were found for women living in Argentina (2.27), Chile (1.95), and Uruguay (2.42) compared with Mexican women, for older (≥60 years) (1.84) compared with younger (≤40 years) women, for basal-like subtype (5.8), luminal B (2.43), and HER2-enriched (2.52) compared with luminal A subtype, and for tumor clinical stages IIB (1.91), IIIA (3.54), and IIIB (3.94) compared with stage IIA women. OS was associated with country of residence, PAM50 intrinsic subtype, age, and tumor stage at diagnosis. While the latter is known to be influenced by access to care, including cancer screening, timely diagnosis and treatment, including access to more effective treatment protocols, it may also influence epigenetic changes that, potentially, impact molecular subtypes. Data derived from heretofore understudied populations with unique geographic ancestry and sociocultural experiences are critical to furthering our understanding of this complexity.
Fil: de Almeida, Liz María. Instituto Nacional de Câncer; Brasil
Fil: Cortés, Sandra. Pontificia Universidad Católica de Chile; Chile
Fil: Vilensky, Marta. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina
Fil: Valenzuela, Olivia. Universidad de Sonora; México
Fil: Cortes Sanabria, Laura. Hospital de Especialidades Centro Medico Nacional Siglo XXI; México
Fil: de Souza, Mirian. Instituto Nacional de Câncer; Brasil
Fil: Barbeito, Rafael Alonso. Universidad de la República; Uruguay
Fil: Abdelhay, Eliana. Instituto Nacional de Câncer; Brasil
Fil: Artagaveytia, Nora. Universidad de la Republica; Uruguay
Fil: Daneri Navarro, Adrian. Universidad de Guadalajara; México
Fil: Llera, Andrea Sabina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina
Fil: Müller, Bettina. Instituto Nacional del Cáncer; Chile
Fil: Podhajcer, Osvaldo Luis. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina
Fil: Velazquez, Carlos. Universidad de Sonora; México
Fil: Alcoba, Elsa. Hospital Maria Curie; Argentina
Fil: Alonso, Isabel. Centro Hospitalario Pereira Rossell; Uruguay
Fil: Bravo, Alicia I.. Hospital Higa Eva Perón; Argentina
Fil: Camejo, Natalia. Universidad de la República; Uruguay
Fil: Carraro, Dirce Maria. A. C. Camargo Cancer Center; Brasil
Fil: Castro, Mónica. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina
Fil: Cataldi, Sandra. Instituto Nacional del Cáncer; Uruguay
Fil: Cayota, Alfonso. Instituto Pasteur de Montevideo; Uruguay
Fil: Cerda, Mauricio. Universidad de Chile; Chile
Fil: Colombo, Alicia. Universidad de Chile; Chile
Fil: Crocamo, Susanne. Instituto Nacional de Câncer; Brasil
Fil: Silva-Garcia, Aida A.. Universidad de Guadalajara; México
Fil: Viña, Stella. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Oncología "Ángel H. Roffo"; Argentina
Fil: Zagame, Livia. Instituto Jalisciense de Cancerología; México
Fil: Jones, Beth. University of Yale; Estados Unidos
Fil: Szklo, Moysés. University Johns Hopkins; Estados Unidos